Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NuvaHealth vs REMEVi

NuvaHealth
Graded #67

Higher grade

vs+3.5999999999999943
REMEVi
Graded #108

Lower grade

The verdict

NuvaHealth takes it — 74/100 to 70.4/100.

NuvaHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuvaHealth (nuvahealth.org) is a LegitScript-certified compounded GLP-1 telehealth platform offering compounded semaglutide starting at $159 first-month and compounded tirzepatide starting at $259 first-month.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuvaHealth +21
75
54
Dose & formulationNuvaHealth +24
88
64
Clinical oversightREMEVi +4
82
86
Labs & monitoringREMEVi +12
53
65
FulfillmentREMEVi +23
74
97
Contract termsREMEVi +14
55
69
NuvaHealth · left barREMEVi · right bar

The numbers

MetricNuvaHealthREMEVi
WeighScore74/10070.4/100
GradeCC
Scorecard rank#67#108
Semaglutide$139/mo (first-month rate, compounded)$199/mo (starting dose, compounded)
Tirzepatide$229/mo (first-month rate, compounded)$269/mo (starting dose, compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
NuvaHealth

Graded #67 · C

Strengths

  • LegitScript Certified seal displayed on the marketing site (the standard third-party telehealth/pharmacy accreditation)
  • Free and fast delivery + 24/7 patient support disclosed on the home page
  • Newark, DE address suggests a US-incorporated entity (vs offshore)
  • $139 first-month price for compounded semaglutide injection is among the cheapest in the US compounded telehealth market
  • $229 first-month price for compounded tirzepatide injection sits in the lower-median range

Where it loses points

  • Standard ongoing monthly price NOT publicly disclosed (gated behind checkout) — patients should ask for the maintenance-dose price before committing
  • Specific legal entity name + state of incorporation NOT publicly disclosed on the home page — material YMYL transparency gap
  • Pharmacy partners NOT publicly named — material YMYL transparency gap
  • Per-state availability NOT enumerated; verify your state ships before purchase
  • Lab work + coaching support NOT publicly disclosed
REMEVi

Graded #108 · C

Strengths

  • The first bilingual GLP-1 clinic — care delivered in English and Spanish by clinicians trained in both, not auto-translated
  • Compounded semaglutide from $199/mo and tirzepatide from $269/mo on the 52-week plan, with the same price every month (no titration price hikes)
  • LegitScript-certified and licensed in all 50 states + DC, with an NPI-verified pharmacy and overnight shipping
  • Transparent all-inclusive pricing with no hidden fees and cancel anytime; full legal suite (Privacy, Terms, HIPAA, Refund)

Where it loses points

  • Lowest pricing requires a 52-week commitment — month-to-month is higher ($279 semaglutide / $339 tirzepatide)
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy or Zepbound
  • The specific compounding pharmacy is not named (described as 'NPI-verified')
  • A newer, patient-founded clinic; press mentions (Fortune, AP, Reuters) are syndicated PR, not editorial endorsements

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard